Study: Amgen drug may bring new approach to treat ITP

12/10/2007 | Bloomberg

Amgen's experimental treatment for idiopathic thrombocytopenic purpura not only reduced the risk of severe bleeding, but also helped preserve a healthy number of platelets in patients with the immune disorder, scientists revealed. The biotech firm is seeking FDA approval to market the drug, labeled AMG-531, while it ramps up development to launch the product as the first to stimulate platelets to treat ITP.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA